目前， 河南省肿瘤医院血液科淋巴瘤病区 有9项淋巴瘤临床研究正在进行，有需要的患者朋友欢迎电话咨询详情。 一项研究 “抗CD19/CD20嵌合抗原受体自体T细胞注射液（C-CAR039）治疗CD19或CD20阳性的复发或难治性大B细胞淋巴瘤的Ib/II期临床研究” （CTR编号 CTR20222827）。该研究已经通过医院伦理委员会的审查（CTMS编号 2023-477）。

目前，河南省肿瘤医院血液科淋巴瘤病区有9项淋巴瘤临床研究正在进行，有需要的患者朋友欢迎电话咨询详情。01一项研究“抗CD19/CD20嵌合抗原受体自体T细胞注射液（C-CAR039）治疗CD19或CD20阳性的复发或难治性大B细胞淋巴瘤的Ib/II期临床研究”（CTR编号 CTR20222827）。该研究已经通过我院伦理委员会的审查（CTMS编号 ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

Figure 1: Transgene expression and phenotype. Figure 2: K14.MYC2 mice exhibit impairment in wound healing. Figure 3: K14.MYC2 primary keratinocytes exhibit a defect in migration. Figure 4: K14 ...

BioLegend), anti-CD19 APC (clone HIB19, BD Pharmigen), anti-CD25 APC (clone 2A3, BD Pharmigen), anti-CD71 FITC (clone CY1G4, BioLegend), anti-Myc FITC or APC (clone 9B11, Cell Signaling, Danvers, MA), ...

MYC is a pleiotropic transcription factor involved in multiple cellular processes. While its mechanism of action and targets are not completely elucidated, it has a fundamental role in cellular ...

4 Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Objectives CD19-targeting chimeric ...

Here, we review the ongoing developments with CAR T cells in the field of autoimmune disorders. We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T ...

Antibodies are proteins that recognize and bind to specific molecules, and so help the immune system to defend the body against foreign substances that are potentially harmful. In some cases, harmless ...

1, 2 In this study, we derived and validated an MYC activation signature that is dissociated from cell cycle/proliferation and showed that this signature is activated in about two-thirds of MM but ...